Axa S.A. Acquires New Shares in MaxCyte, Inc. (NASDAQ:MXCT)

AXA S.A. purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 986,897 shares of the company's stock, valued at approximately $4,105,000. AXA S.A. owned about 0.93% of MaxCyte as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Mirabella Financial Services LLP purchased a new position in MaxCyte in the 4th quarter worth about $15,392,000. River Global Investors LLP boosted its stake in MaxCyte by 57.7% in the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company's stock worth $13,494,000 after purchasing an additional 1,190,630 shares during the period. Dimensional Fund Advisors LP grew its position in MaxCyte by 15.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,429,071 shares of the company's stock worth $5,945,000 after purchasing an additional 191,088 shares in the last quarter. Chevy Chase Trust Holdings LLC raised its stake in MaxCyte by 0.6% during the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company's stock valued at $5,574,000 after purchasing an additional 7,781 shares during the period. Finally, CenterBook Partners LP lifted its holdings in shares of MaxCyte by 48.2% in the fourth quarter. CenterBook Partners LP now owns 867,009 shares of the company's stock valued at $3,607,000 after purchasing an additional 281,923 shares in the last quarter. 68.81% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on MXCT shares. BTIG Research set a $6.00 price objective on MaxCyte and gave the stock a "buy" rating in a research note on Wednesday, March 12th. Stifel Nicolaus dropped their price objective on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th.

MaxCyte Price Performance

Shares of MaxCyte stock traded down $0.06 during midday trading on Friday, hitting $2.37. The company had a trading volume of 1,936,084 shares, compared to its average volume of 540,657. The business's 50 day simple moving average is $2.84 and its two-hundred day simple moving average is $3.62. The stock has a market cap of $251.98 million, a PE ratio of -6.97 and a beta of 1.38. MaxCyte, Inc. has a 1-year low of $2.21 and a 1-year high of $5.26.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $10.39 million for the quarter, compared to analyst estimates of $9.05 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. On average, sell-side analysts expect that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.